Search

Your search keyword '"Shaw, Patricia A."' showing total 860 results
Start Over Author "Shaw, Patricia A."
860 results on '"Shaw, Patricia A."'

203. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome

Author

Parker, William A. E., Orme, Rachel C., Hanson, Jessica, Stokes, Hannah M., Bridge, Claire M., Shaw, Patricia A., Sumaya, Wael, Thorneycroft, Kirstie, Petrucci, Giovanna, Porro, Benedetta, Judge, Heather M., Ajjan, Ramzi A., Rocca, Bianca, Storey, Robert F., Petrucci, Giovanna (ORCID:0000-0002-9280-3673), Rocca, Bianca (ORCID:0000-0001-8304-6423), Parker, William A. E., Orme, Rachel C., Hanson, Jessica, Stokes, Hannah M., Bridge, Claire M., Shaw, Patricia A., Sumaya, Wael, Thorneycroft, Kirstie, Petrucci, Giovanna, Porro, Benedetta, Judge, Heather M., Ajjan, Ramzi A., Rocca, Bianca, Storey, Robert F., Petrucci, Giovanna (ORCID:0000-0002-9280-3673), and Rocca, Bianca (ORCID:0000-0001-8304-6423)

Abstract

Higher aspirin doses may be inferior in ticagrelor-treated acute coronary syndrome (ACS) patients and reducing bleeding risk whilst maintaining antithrombotic benefits could improve outcomes. We characterized the pharmacodynamics of a novel dual-antiplatelet-therapy regimen consisting of very-low-dose twice-daily (BD) aspirin with standard-dose ticagrelor. A total of 20 ticagrelor-treated ACS patients entered a randomized crossover to take aspirin 20 mg BD (12-hourly) during one 14-day period and 75 mg once-daily (OD) in the other. After 14 days of treatment, serum thromboxane (TX)B 2 and light-transmittance aggregometry were assessed pre- and 2 h post-morning-dose, bleeding time was measured post-dose, and TXA 2 and prostacyclin stable metabolites were measured in urine collected 2 h post-morning-dose. Data are expressed as mean ± SD. After 14 days treatment, serum TXB 2 levels were significantly greater 2 h post-dosing with aspirin 20 mg BD vs. 75 mg OD (3.0 ± 3.6 ng/mL vs. 0.8 ± 1.9 ng/mL; p = 0.018) whereas pre-dosing levels were not significantly different (3.5 ± 4.1 ng/mL vs. 2.5 ± 3.1 ng/mL, p = 0.23). 1-mmol/L arachidonic acid-induced platelet aggregation was similarly inhibited by both regimens pre-dose (8.5 ± 14.3% vs. 5.1 ± 3.6%, p = 0.24) and post-dose (8.7 ± 14.2% vs. 6.6 ± 5.3%; p = 0.41). Post-dose bleeding time was shorter with 20 mg BD (680 ± 306 s vs. 834 ± 386 s, p = 0.02). Urinary prostacyclin and TX metabolite excretion were not significantly different. In conclusion, compared to aspirin 75 mg OD, aspirin 20 mg BD provided consistent inhibition of platelet TXA 2 release and aggregation, and improved post-dose hemostasis, in ticagrelor-treated ACS patients. Further studies are warranted to assess whether this regimen improves the balance of clinical efficacy and safety.

Published
2019

205. Additional file 3: of Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors

Author

S. Yang, Lheureux, Stephanie, Karakasis, Katherine, Burnier, Julia, Bruce, Jeffery, Clouthier, Derek, Arnavaz Danesh, Quevedo, Rene, Dowar, Mark, Youstina Hanna, Tiantian Li, Lu, Lin, Xu, Wei, Clarke, Blaise, Ohashi, Pamela, Shaw, Patricia, Pugh, Trevor, and Oza, Amit

Subjects
genetic structures, eye diseases
Abstract

CNV segment size as distribution per sample. Distribution of CNV segment size as percentage of chromosome arm in each sequenced tumor sample. Sequenza estimated sample ploidy and the threshold used for determining copy number amplification is shown for each sample as colored horizontal lines. (PDF 34 kb)

Published
2018
Full Text
View/download PDF

206. Additional file 2: of Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors

Author

S. Yang, Lheureux, Stephanie, Karakasis, Katherine, Burnier, Julia, Bruce, Jeffery, Clouthier, Derek, Arnavaz Danesh, Quevedo, Rene, Dowar, Mark, Youstina Hanna, Tiantian Li, Lu, Lin, Xu, Wei, Clarke, Blaise, Ohashi, Pamela, Shaw, Patricia, Pugh, Trevor, and Oza, Amit

Abstract

Supplementary methods for the manuscript. (PDF 112 kb)

Published
2018
Full Text
View/download PDF

207. Additional file 1: of Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors

Author

S. Yang, Lheureux, Stephanie, Karakasis, Katherine, Burnier, Julia, Bruce, Jeffery, Clouthier, Derek, Arnavaz Danesh, Quevedo, Rene, Dowar, Mark, Youstina Hanna, Tiantian Li, Lu, Lin, Xu, Wei, Clarke, Blaise, Ohashi, Pamela, Shaw, Patricia, Pugh, Trevor, and Oza, Amit

Abstract

Supplementary figures for the manuscript. (PDF 14062 kb)

Published
2018
Full Text
View/download PDF

208. Launching quality improvement in histology

Author

Shaw, Patricia A.

Subjects
Quality management, Biomedical laboratories -- Quality management, Histology -- Quality management, Medical laboratories -- Quality management
Abstract

An organized, well-defined plan can yield gratifying results in this specialized area of the laboratory. QUALITY ASSURANCE in histology can present special challenges because it is so elusive. Instead of [...]

Published
1993

210. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome

Author

Parker, William A.E., primary, Orme, Rachel C., additional, Hanson, Jessica, additional, Stokes, Hannah M., additional, Bridge, Claire M., additional, Shaw, Patricia A., additional, Sumaya, Wael, additional, Thorneycroft, Kirstie, additional, Petrucci, Giovanna, additional, Porro, Benedetta, additional, Judge, Heather M., additional, Ajjan, Ramzi A., additional, Rocca, Bianca, additional, and Storey, Robert F., additional

Published
2019
Full Text
View/download PDF

212. TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses

Author

Mandilaras, Victoria, primary, Garg, Swati, additional, Cabanero, Michael, additional, Tan, Qian, additional, Pastrello, Chiara, additional, Burnier, Julia, additional, Karakasis, Katherine, additional, Wang, Lisa, additional, Dhani, Neesha C, additional, Butler, Marcus O, additional, Bedard, Philippe L, additional, Siu, Lillian L, additional, Clarke, Blaise, additional, Shaw, Patricia Ann, additional, Stockley, Tracy, additional, Jurisica, Igor, additional, Oza, Amit M, additional, and Lheureux, Stephanie, additional

Published
2019
Full Text
View/download PDF

214. Evolutionary active vision system: from 2D to 3D.

Author

Lanihun, Olalekan, Tiddeman, Bernie, Shaw, Patricia, and Tuci, Elio

Subjects
AFFERENT pathways, VISION, HUMANOID robots, BIOLOGICAL systems, MOTOR ability, EYE movements, PHYSIOLOGICAL adaptation
Abstract

Biological vision incorporates intelligent cooperation between the sensory and the motor systems, which is facilitated by the development of motor skills that help to shape visual information that is relevant to a specific vision task. In this article, we seek to explore an approach to active vision inspired by biological systems, which uses limited constraints for motor strategies through progressive adaptation via an evolutionary method. This type of approach gives freedom to artificial systems in the discovery of eye-movement strategies that may be useful to solve a given vision task but are not known to us. In the experiment sections of this article, we use this type of evolutionary active vision system for more complex natural images in both two-dimensional (2D) and three-dimensional (3D) environments. To further improve the results, we experiment with the use of pre-processing the visual input with both the uniform local binary patterns (ULBP) and the histogram of oriented gradients (HOG) for classification tasks in the 2D and 3D environments. The 3D experiments include application of the active vision system to object categorisation and indoor versus outdoor environment classification. Our experiments are conducted on the iCub humanoid robot simulator platform. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

215. High‐resolution epigenomic liquid biopsy for noninvasive phenotyping in pregnancy.

Author

Chu, Tianjiao, Shaw, Patricia, McClain, Lora, Simhan, Hyagriv, and Peters, David

Abstract

Objective: We explored the potential of genome‐wide epigenomic liquid biopsy for the comprehensive analysis of cell‐free DNA (cfDNA) methylation signatures in maternal plasma in early gestation. Method: We used solution phase hybridization for targeted region capture of bisulfite‐converted DNA obtained from plasma of pregnant women in early gestation and nonpregnant female controls. Results: Targeted sequencing of ~80.5 Mb of the plasma methylome generated an average read depth across all 17 plasma samples of ~42x. We used these data to explore the pregnancy‐specific characteristics of cfDNA methylation in plasma and found that pregnancy resulted in clearly detectable global alterations in DNA methylation patterns that were influenced by genomic location. We analyzed similar, previously published, data from first‐trimester maternal leukocyte populations and gestational age–matched chorionic villus (CV) and confirmed that tissue‐specific DNA methylation signatures in these samples had a significant influence on global and gene‐specific methylation in the plasma of pregnant women. Conclusion: We describe an approach for targeted epigenomic liquid biopsy in pregnancy and discuss our findings in the context of noninvasive prenatal testing with respect to phenotypic pregnancy monitoring and the early detection of complex gestational phenotypes such as preeclampsia and preterm birth. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

216. Chromosome 15q13.3 microduplications are associated with treatment refractory major depressive disorder.

Author

McClain, Lora, Segreti, Anna M., Nau, Sharon, Shaw, Patricia, Finegold, David N., Pan, Lisa A., and Peters, David G.

Subjects
MENTAL depression, DNA copy number variations, CHROMOSOMES, CEREBROSPINAL fluid
Abstract

Major depressive disorder (MDD) affects approximately 15 million Americans. Approximately 2 million of these are classified as being refractory to treatment (TR‐MDD). Because of the lack of available therapies for TR‐MDD, and the high risk of suicide, there is interest in identifying new treatment modalities and diagnostic methods. Understanding of the impact of genomic copy number variation in the etiology of a variety of neuropsychiatric phenotypes is increasing. Low copy repeat elements at 15q13.3 facilitate non‐allelic homologous recombination, resulting in recurrent copy number variants (CNVs). Numerous reports have described association between microdeletions in this region and a variety of neuropsychiatric phenotypes, with CHRNA7 implicated as a candidate gene. However, the pathogenicity of 15q13.3 duplications is less clear. As part of an ongoing study, in which we have identified a number of metabolomic anomalies in spinal fluid from TR‐MDD patients, we also evaluated genomic copy number variation in patients (n = 125) and controls (n = 26) via array‐based copy number genomic hybridization (CGH); the case frequency was compared with frequencies reported in a prior study as well as a larger population‐sized cohort. We identified five TR‐MDD patients with microduplications involving CHRNA7. CHRNA7 duplications are the most common CNVs identified by clinical CGH in this cohort. Therefore, this study provides insight into the potential involvement of CHRNA7 duplications in the etiology of TR‐MDD and informs those involved with care of affected individuals. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

217. A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium

Author

Lheureux, Stephanie, primary, Tinker, Anna, additional, Clarke, Blaise, additional, Ghatage, Prafull, additional, Welch, Stephen, additional, Weberpals, Johanne I., additional, Dhani, Neesha C., additional, Butler, Marcus O., additional, Tonkin, Katia, additional, Tan, Qian, additional, Tan, David S.P., additional, Brooks, Kelly, additional, Ramsahai, Janelle, additional, Wang, Lisa, additional, Pham, Nhu-An, additional, Shaw, Patricia A., additional, Tsao, Ming S., additional, Garg, Swati, additional, Stockley, Tracey, additional, and Oza, Amit M., additional

Published
2018
Full Text
View/download PDF

218. Regulatory T Cells in Ovarian Cancer Are Characterized by a Highly Activated Phenotype Distinct from that in Melanoma

Author

Toker, Aras, primary, Nguyen, Linh T., additional, Stone, Simone C., additional, Yang, S.Y. Cindy, additional, Katz, Sarah Rachel, additional, Shaw, Patricia A., additional, Clarke, Blaise A., additional, Ghazarian, Danny, additional, Al-Habeeb, Ayman, additional, Easson, Alexandra, additional, Leong, Wey L., additional, McCready, David R., additional, Reedijk, Michael, additional, Guidos, Cynthia J., additional, Pugh, Trevor J., additional, Bernardini, Marcus Q., additional, and Ohashi, Pamela S., additional

Published
2018
Full Text
View/download PDF

219. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study

Author

Visvanathan, Kala, primary, Shaw, Patricia, additional, May, Betty J., additional, Bahadirli-Talbott, Asli, additional, Kaushiva, Alpana, additional, Risch, Harvey, additional, Narod, Steven, additional, Wang, Tian-Li, additional, Parkash, Vinita, additional, Vang, Russell, additional, Levine, Douglas A., additional, Soslow, Robert, additional, Kurman, Robert, additional, and Shih, Ie-Ming, additional

Published
2018
Full Text
View/download PDF

220. NovelEPC1gene fusions in endometrial stromal sarcoma

Author

Dickson, Brendan C., primary, Lum, Amy, additional, Swanson, David, additional, Bernardini, Marcus Q., additional, Colgan, Terrence J., additional, Shaw, Patricia A., additional, Yip, Stephen, additional, and Lee, Cheng-Han, additional

Published
2018
Full Text
View/download PDF

223. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap

Author

McCuaig, Jeanna M, primary, Stockley, Tracy L, additional, Shaw, Patricia, additional, Fung-Kee-Fung, Michael, additional, Altman, Alon D, additional, Bentley, James, additional, Bernardini, Marcus Q, additional, Cormier, Beatrice, additional, Hirte, Hal, additional, Kieser, Katharina, additional, MacMillan, Andree, additional, Meschino, Wendy S, additional, Panabaker, Karen, additional, Perrier, Renee, additional, Provencher, Diane, additional, Schrader, Kasmintan A, additional, Serfas, Kimberly, additional, Tomiak, Eva, additional, Wong, Nora, additional, Young, Sean S, additional, Gotlieb, Walter Henri, additional, Hoskins, Paul, additional, and Kim, Raymond H, additional

Published
2018
Full Text
View/download PDF

224. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma

Author

Lheureux, Stephanie, primary, Butler, Marcus O., additional, Clarke, Blaise, additional, Cristea, Mihaela C., additional, Martin, Lainie P., additional, Tonkin, Katia, additional, Fleming, Gini F., additional, Tinker, Anna V., additional, Hirte, Hal W., additional, Tsoref, Daliah, additional, Mackay, Helen, additional, Dhani, Neesha C., additional, Ghatage, Prafull, additional, Weberpals, Johanne, additional, Welch, Stephen, additional, Pham, Nhu-An, additional, Motta, Vinicius, additional, Sotov, Valentin, additional, Wang, Lisa, additional, Karakasis, Katherine, additional, Udagani, Smitha, additional, Kamel-Reid, Suzanne, additional, Streicher, Howard Z., additional, Shaw, Patricia, additional, and Oza, Amit M., additional

Published
2018
Full Text
View/download PDF

227. A phase Ib trial of pembrolizumab (Pembro) following adoptive cell therapy (ACT) in patients with platinum-resistant ovarian cancer; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) trial.

Author

Ethier, Josee-Lyne, primary, Bonilla, Luisa, additional, Boross-Harmer, Sarah, additional, Bouchard-Fortier, Genevieve, additional, Cipollone, Jane, additional, Clarke, Blaise A., additional, Dhani, Neesha C., additional, Easson, Alexandra Maria, additional, Franke, Norman, additional, Goldstein, David Paul, additional, Lheureux, Stephanie, additional, Majeed, Habeeb, additional, May, Taymaa, additional, Reedijk, Michael, additional, Rouzbahman, Marjan, additional, Saibil, Sam, additional, Shaw, Patricia Ann, additional, Ohashi, Pamela S, additional, Nguyen, Linh T., additional, and Butler, Marcus O., additional

Published
2018
Full Text
View/download PDF

230. Glycaemic Index, Glycaemic Load and dietary fibre characteristics of two commercially available fruit smoothies

Author

Saltaouras, Georgios, Shaw, Patricia K., Fraser, Ann C., Hawes, Chris, Smith, Harry, Handley, Louisa, Whitby, Helen, Thondre, Sangeetha P., Lightowler, Helen J., Saltaouras, Georgios, Shaw, Patricia K., Fraser, Ann C., Hawes, Chris, Smith, Harry, Handley, Louisa, Whitby, Helen, Thondre, Sangeetha P., and Lightowler, Helen J.

Abstract

In light of the updated Eatwell Guide and the corresponding change in the consumption of fruit smoothies, the aim of this study was to measure the glycaemic index and load of two commercial fruit smoothies and to investigate the retention of dietary fibre following production. In vitro analysis was performed to identify fibre material (cellulose and pectins) using calcofluor staining and immunocytochemical labelling. A repeated measures crossover study was conducted (n 10) to determine the Glycaemic Index (GI) and Glycaemic Load (GL) of the smoothies. Results showed that dietary fibre was still present in the smoothies after processing (16.9-17.5% cellular material by dry weight). The GI was low for both smoothies (39 and 36), whereas the GL was medium and borderline-low, respectively (11.4 and 9.7). The retention of fibre in these smoothies may have a potential positive effect on glycaemic response and may contribute to daily fibre requirements.

Published
2018

232. Lighting up networks

Author

Shaw, Patricia and Critchley, Bill

Subjects
Work groups -- Models, Business, Business, general
Abstract

The creation of network teams is a new concept in the field of team building and task-based organizational networks, and can help people work together even if they belong to organizations with multi-locational membership. Following the network metaphor, it is evident that the success of such a framework depends largely on the creation of an effective communication system, the ability of the network to connect into the political system and the manner by which members exercise their power.

Published
1994

233. Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society

Author

Dierssen, Mara, Herault, Yann, Helguera, Pablo, Martínez de Lagran, Maria, Vazquez, Anna, Christian, Bradley, Carmona-Iragui, Maria, Wiseman, Frances, Mobley, William, Fisher, Elizabeth M.C., Brault, Veronique, Esbensen, Anna, Jacola, Lisa M., Potier, Marie Claude, Hamlett, Eric D., Abbeduto, Leonard, del Hoyo Soriano, Laura, Busciglio, Jorge, Iulita, Maria Florencia, Crispino, John, Malinge, Sébastien, Barone, Eugenio, Perluigi, Marzia, Costanzo, Floriana, Delabar, Jean Maurice, Bartesaghi, Renata, Dekker, Alain D., De Deyn, Peter, Fortea Ormaechea, Juan, Shaw, Patricia A., Haydar, Tarik F., Sherman, Stephanie L., Strydom, André, and Bhattacharyya, Anita

Abstract

Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6–9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer’s disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar­ma­cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.

Published
2021
Full Text
View/download PDF

237. Correspondence

Author

Crawford, W. B. S., Sutherland, A., Hart, C. R., Craigen, A. A., Reckitt, V. B., Nicholson, N. G., Jones, Ivor M., Cridland, Nigel, Shaw, Patricia, Bolton, Anne, Spiller, V., and Robinson, J. F.

Published
1962

239. Editorial

Author

Patton, Faye, Shaw, Patricia, Ekkel, Gary, and Todzy, Joerg

Published
1991

244. Additional file 1: of Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

Author

Stockley, Tracy, Oza, Amit, Berman, Hal, Leighl, Natasha, Knox, Jennifer, Shepherd, Frances, Chen, Eric, Krzyzanowska, Monika, Neesha Dhani, Joshua, Anthony, Ming-Sound Tsao, Serra, Stefano, Clarke, Blaise, Roehrl, Michael, Zhang, Tong, Mahadeo Sukhai, Califaretti, Nadia, Mateya Trinkaus, Shaw, Patricia, Kwast, Theodorus Van Der, Wang, Lisa, Virtanen, Carl, Kim, Raymond, Albiruni Razak, Hansen, Aaron, Yu, Celeste, Pugh, Trevor, Kamel-Reid, Suzanne, Siu, Lillian, and Bedard, Philippe

Abstract

Supplementary methods and Tables S1â S4. (DOCX 148 kb)

Published
2016
Full Text
View/download PDF

248. Implementing a Cervical Sentinel Lymph Node Biopsy Program: Quality Improvement in Gynaecologic Oncology

Author

Cusimano, Maria C., primary, Walker, Rachel, additional, Bernardini, Marcus Q., additional, Bouchard-Fortier, Geneviève, additional, Laframboise, Stephane, additional, May, Taymaa, additional, Murphy, Joan, additional, Rosen, Barry, additional, Covens, Al, additional, Clarke, Blaise, additional, Shaw, Patricia, additional, Rouzbahman, Marjan, additional, Mohan, Ravi, additional, and Ferguson, Sarah E., additional

Published
2017
Full Text
View/download PDF

249. Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach

Author

Samimi, Goli, primary, Bernardini, Marcus Q., additional, Brody, Lawrence C., additional, Caga-anan, Charlisse F., additional, Campbell, Ian G., additional, Chenevix-Trench, Georgia, additional, Couch, Fergus J., additional, Dean, Michael, additional, de Hullu, Joanne A., additional, Domchek, Susan M., additional, Drapkin, Ronny, additional, Spencer Feigelson, Heather, additional, Friedlander, Michael, additional, Gaudet, Mia M., additional, Harmsen, Marline G., additional, Hurley, Karen, additional, James, Paul A., additional, Kwon, Janice S., additional, Lacbawan, Felicitas, additional, Lheureux, Stephanie, additional, Mai, Phuong L., additional, Mechanic, Leah E., additional, Minasian, Lori M., additional, Myers, Evan R., additional, Robson, Mark E., additional, Ramus, Susan J., additional, Rezende, Lisa F., additional, Shaw, Patricia A., additional, Slavin, Thomas P., additional, Swisher, Elizabeth M., additional, Takenaka, Masataka, additional, Bowtell, David D., additional, and Sherman, Mark E., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results